Carmen Del Rio
Cordoba, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Cannabidiol markedly alleviates skin and liver fibrosis.
Journal: Frontiers in pharmacology
Published: June 29, 2022
Environmental Conditions of Dance Rooms and Its Impact on Dance Conservatories Teachers' Health (An Andalusian Study).
Journal: International journal of environmental research and public health
Published: April 20, 2021
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
Journal: Molecular and cellular neurosciences
Published: October 24, 2020
EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis.
Journal: Biochemical pharmacology
Published: June 09, 2018
VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways.
Journal: British journal of pharmacology
Published: December 18, 2017
Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.
Journal: British journal of pharmacology
Published: March 28, 2017
VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease.
Journal: Scientific reports
Published: January 29, 2016
The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways.
Journal: Scientific reports
Published: October 09, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026